Goldman Sachs
BIVI icon

Goldman Sachs’s BioVie BIVI Stock Holding History

Goldman Sachs’s Portfolio BIVI Stock Details BIVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-616
Closed -$24.7K – 5821
2024
Q2 		$24.7K Buy
+616
New +$29.5K ﹤0.01% 5506
2023
Q2 		– Sell
-241
Closed -$195K – 5757
2023
Q1 		$195K Buy
+241
New +$160K ﹤0.01% 5310

Other funds holding BIVI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ZIG
Zullo Investment Group Scranton, Pennsylvania $264M AUM 26.77% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
UCMOK
United Capital Management of KS Salina, Kansas $660M AUM 50.85% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Goldman Sachs's BIVI Position: Q3 2024 in Review

Goldman Sachs sold out of BioVie (BIVI) in Q3 2024, closing a stake of 616 shares — an estimated $24.7K sold.

Goldman Sachs first reported a position in BIVI in Q1 2023 and held it in 2 quarters. The position peaked at $195K in Q1 2023. 25 funds tracked by Wall St. Rank hold BIVI as of Q3 2024.

  • Goldman Sachs reported no remaining BioVie position as of Q3 2024 after selling out during the quarter.
  • Goldman Sachs sold 616 BioVie shares in Q3 2024, an estimated $24.7K.
  • Goldman Sachs first reported a position in BioVie in Q1 2023 and held it in 2 quarters.
  • Goldman Sachs's BioVie position peaked at $195K in Q1 2023.
  • 25 funds tracked by Wall St. Rank held BioVie as of Q3 2024.

Based on Goldman Sachs's 13F filing for Q3 2024, filed 14 Nov 2024.